Additional Assays

Secondary assays depend on the project. Where the primary screen was a cell-based assay, the secondary assay may be a radioligand competition binding assay. In other cases, such as where the primary screen was a biochemical assay, the secondary assay may be a cellular assay, and may be functional or mechanistic. One of the issues that may arise at this stage is that compounds with reasonable activity in the primary assay may not show activity in the secondary assay. There can be a number of reasons for this, including insufficient potency, inability of the compound to get into cells, or a higher intracellular concentration of the natural ligand (e.g., ATP) if the inhibitor is a competitive inhibitor. It is often necessary at this stage to prepare additional compounds in the series to get compounds of sufficient potency and/or permeability so that cellular activity can be demonstrated. 

Throughout the period of the hit-to-lead process, additional analogs may be prepared to improve understanding of the SAR of the series to give an impression of whether chemistry space in the series is limited and to show that analogs can be prepared in a timely manner. 

If hits with good properties were selected at the outset, we can hope to arrive at the end of the hit-to-lead process with a series of compounds meeting our lead series criteria, where issues have been flagged and appear tractable. These compounds then provide the launching point for the next phase, lead optimization. 

---

In summary, preliminary results from two animal models (rabbit and mouse) indicate that poly(N-palmitoylhydroxyproline ester) elicits a very mild, local tissue response that compares favorably with the responses observed for established biomaterials such as medical grade stainless steel or poly(lactic acid)/poly(glycolic acid) implants. At this point, additional assays need to be performed to evaluate possible allergic responses, as well as systemic toxic effects, carcinogenic, teratogenic, or mutagenic activity, and adaptive responses. 

Generally, all of the assays used for characterization of hits in terms of potency, selectivity, function, and or cellular activity will continue to be used to characterize new compounds synthesized to identify leads. However, additional assays will normally be added to characterize compound selectivity more fully, to provide additional evidence that compounds are acting on the desired pathway and by the desired mechanism. 

Bioassays. Four bioassays were developed to test the phytotoxic affect of spikerush leachate. Two assays involving target plants (hydrilla and sago pondweed) were tested at the explant level. Two additional assays were developed, one involving whole plants... 

Additional assays used in early pharmaceutical property profiles usually include plasma protein binding, individual cytochrome P450 assays, stability in the presence of serum, production of metabolites likely to be involved in covalent binding to biomolecules, and interaction with efflux pumps ... 

Additional assays included a selectivity evaluation and cytotoxicity assay where both good selectivity and low cytotoxicity were documented. The extract was also tested on unrelated viruses and other influenza viruses. Extract A4 was the only one to maintain the activity through secondary screening, and with that as a target, purification of the active extract commenced. 

Additional assays have surfaced on both ends of the scale of complexity. Single end point assays such as those for a host of receptor binding and activation assays and enzyme activity modulation assays have been developed and applied to alternative developmental toxicity testing. These assays can be carried out in a... 

IPEC-US (intended clinical route)a Acute oral and dermal toxicity, skin and eye irritation, and skin sensitization. Bacterial gene mutation and chromosome damage. ADME (intended route). 28-day toxicity (2 species by intended clinical route) Short-term use studies. 90-day toxicity (most appropriate species). Teratology (rat and/or rabbit). Genotoxicity assays. Additional assays (conditional) 1 Short-/midterm studies. One-generation reproduction. Chronic toxicity (rodent and nonrodent) and carcinogenicity (conditional)... 

Most of the reported in vivo data presented in the literature involves the infection of donor mice with a strain of P. berghe [61]. After a parasitemia of circa 30% is achieved in the donor mice, a blood sample is taken, diluted, and injected into experimental and control mice. The parasitemia load is regularly monitored for 3 to 7 days after infection by blood smear analysis as a function of drug dose. While in vivo efficacy assays reveal the true scope of a potential antimalarial s efficacy, the methods are very expensive. Consequently, additional assays have been developed to rapidly assess the effectiveness of lead heme aggregation inhibitors. 

Naesdal et al. [144] studied the pharmacokinetics of 14C-omeprazole and its metabolites after single intravenous and oral doses of 20 0 mg, respectively, to 12 patients with chronic renal insufficiency. Blood samples for determination of total radioactivity, omeprazole, hydroxyomeprazole, sulfone, and sulfide were taken for 24 h. Urine was collected over 96 h for determination of total radioactivity and during the first 24 h for additional assay of omeprazole and metabolites. The mean systemic availability was 70% and the mean plasma t1/z of omeprazole was 0.6 h. 

The toxicity of effluents discharged into the aquatic environment is also classified using the numerical value of the PE index obtained in a test on an undiluted sample. However, for samples in which PE > 50%, additional assays are conducted in which increasing dilutions of the examined samples are tested. The L(E)C50 values obtained are converted into TU. Depending on the numerical values of the TU index, effluent samples are classified according to the criteria listed in Table 9.8. 

The colonies should be examined and counted at between days 8 and 10, with the precise time of scoring being dictated by the time at which colonies in the control plates reach a diameter of 2 mm. Leaving the assays more than 1 d beyond this time can often result in the inhibitory effect being lost owing to the overgrowth of the colonies in the inhibited plates. This direct addition assay has been used to measure the inhibitory activity of both MIP-la and other stem-cell inhibitory molecules such as TGF-p (12,13). 

Specifically, the direct addition assay is carried out as follows ... 

Endpoint assays such as proliferation or cytotoxicity assays are routinely used for functional assessments. For these assessments, primary cells, transformed cells, or cells transfected with the target receptor are exposed to range of concentrations of the test article. Proliferation or cytoxicity is then measured using a variety of methods such as crystal violet vital dye staining, MTT/MTS incorporation, or a luminescence readout like ATP lite. In addition, assays that analyze phosphorylation of specific transcription factors, or release of specific cytokines and chemokines, are also common. Figure 9.5 illustrates the measure of functional consequences of receptor-test article interaction by quantifying cytokine release. Cells from the species under evaluation were cultured in the presence of serial dilutions of the test article or control reagents, and supernatants harvested for determination of cytokine levels by ELISA (i.e.,... 

The following discussions and assay descriptions are related to cytochrome P450 inhibition. Most drug interaction studies are related to P450 isoenzymes. Nevertheless, other enzyme systems may contribute to significant drug interactions such as transporter (e.g. Floren 1997 Abel 2001) phase II enzymes (e.g. Diet-mann 1976 Zucker 2001 Rayer 2001 Williams 2004), or cytosolic enzymes (Obach 2004). Additional assays related to pgp, phase II or cytosolic enzyme interactions are published in literature (e.g. Polli 2001 Schwab 2002 Schinkel 2003 www.bdbiosciences.com, Obach 2004). 

Modifications of the standard battery may be necessary for some classes, e.g., antibiotics which are toxic to bacteria or e.g., for compounds like topoisomerase inhibitors which interfere with the mammalian cell replication system. A selection of additional assays is being proposed, further modifications may be acceptable via discussion in the ICH Maintenance Process. Alternative strategies may consider assays like the in vivo Comet assay (single cell gel electrophoresis measuring DNA strand breaks) or gene mutation tests with transgenic animals or in vivo DNA adduct studies. 

Certain circumstances might arise where the bioanalyst wants to examine a recombinant protein preparation for low level protein impurities but a suitable antiserum is unavailable and the variability and nonspecificity of silver staining is unacceptable. An additional assay would be a Western blot analysis after derivatization of the protein mixture with Sanger s reagent... 

Third, efficient use of Experimental Biochemistry requires that you perform and interpret many calculations during the course of the laboratory sessions. Specifically, laboratory work for introductory biochemistry, unlike many introductory laboratory courses, frequently requires you to use the results of one assay to prepare and perform additional assays. Thus, you will have to understand fully what you are doing at each step and why you are doing it. 

DNA repair can be detected by the same assays (alkaline elution and Comet) that are used to detect DNA damage, but with various time intervals between the end of exposure and the time of sampling. An additional assay for assessing DNA repair has been utilized for many years, namely the unscheduled DNA synthesis (UDS) assay. The endpoint measured is the uptake of tritiated thymidine into DNA repair sites following exposure. The sensitivity of the assay is relatively low, especially in vivo, and this limits its predictive value for hazard identification. Thus, a negative response in a UDS assay has very limited value because of this low sensitivity. 

Additional assays are dependent on the judgment of the data evaluator. They may include, but are not lunited to screening for endocrine modulators or tests to determine if findings in animals are relevant to humans. 

---